Should furosemide (Lasix) be used in a patient with heart failure with preserved ejection fraction and acute kidney injury, and what dosing strategy is recommended?

Furosemide in HFpEF with AKI: Use with Caution and Close Monitoring

Loop diuretics, specifically furosemide, should be used in HFpEF patients with AKI only when clinically evident volume overload is present (pulmonary crackles, elevated jugular venous pressure, peripheral edema), but they must be administered cautiously because AKI predicts poor diuretic response and these patients are at high risk for further renal deterioration. 1

When to Use Furosemide

• Indication: Furosemide is appropriate only when there is objective evidence of congestion—bilateral lung crackles, elevated JVP, peripheral edema, or positive fluid balance 1, 2
• Contraindication: Do not use furosemide to prevent or treat AKI itself; it does not improve renal recovery or reduce mortality in the absence of volume overload 1
• Predictors of poor response that warrant extreme caution:
  • Systolic blood pressure <90 mmHg 3, 4, 1
  • Severe hyponatremia (Na <130–135 mEq/L) 3, 4, 1
  • Metabolic acidosis 3, 4, 1

The 2024 systematic review of HFpEF guidelines confirms that diuretics provide symptomatic relief but have no proven prognostic benefit in HFpEF, and may even stimulate neurohormonal activation 5. This makes the risk-benefit calculation in AKI even more delicate.

Initial Dosing Strategy

• Diuretic-naïve patients: Start with 20–40 mg IV furosemide as a slow bolus over 1–2 minutes 3, 4, 6, 1
• Patients on chronic oral diuretics: Give at least twice the total daily oral dose IV (e.g., 40 mg PO daily → ≥80 mg IV) 3, 4, 6, 1
• Early dose limits to minimize toxicity:
  • First 6 hours: <100 mg total 3, 4, 6, 1
  • First 24 hours: <240 mg total 3, 4, 6, 1
  • Maximum daily dose: 600 mg 6, 1

The FDA label warns that furosemide is a potent diuretic that can cause profound diuresis with water and electrolyte depletion, requiring careful medical supervision 2.

Bolus vs. Continuous Infusion

In HFpEF specifically, intermittent bolus is preferred over continuous infusion. The 2018 ROPA-DOP trial—the only randomized trial specifically in HFpEF patients with acute heart failure—found that continuous infusion was associated with significantly greater creatinine rise (16% vs. 4.6%, p=0.02) and higher risk of worsening renal function (OR 4.32, p=0.02) compared to intermittent bolus 7. This contrasts with general heart failure data showing equivalence 8, highlighting that HFpEF patients with AKI are particularly vulnerable to continuous infusion.

• If bolus is chosen: Administer 20–40 mg IV every 6–8 hours initially 6
• If continuous infusion must be used: Loading dose 40 mg IV, then 5–20 mg/hour (maximum 40 mg/hour) 6, 1

Intensive Monitoring Protocol

Every 1–4 Hours

• Hourly urine output (urinary catheter strongly recommended) 3, 6, 1
• Blood pressure 3, 6, 1
• Clinical congestion assessment (lung crackles, JVP, peripheral edema) 3, 6, 1

Daily

• Body weight at the same time each day 3, 6, 1
• Serum electrolytes: potassium, sodium, magnesium 3, 6, 1
• Renal function: creatinine and BUN 3, 6, 1
• Strict intake-output records 3, 6

Interpreting Creatinine Changes

• Rise <30% from baseline: Expected during effective decongestion; continue therapy 6, 1
• Rise >30% with persistent congestion: Signals worsening heart failure, not volume depletion—intensify therapy rather than stop diuretics 6, 1
• Rise >30% with resolved congestion: Consider true volume depletion; reduce or hold diuretics 1

A 2012 review emphasizes that transient worsening renal function during acute HF treatment may not portend poor prognosis, and patients with fluid overload may benefit from aggressive fluid removal despite rising creatinine 9.

Managing Diuretic Resistance (Sequential Nephron Blockade)

When loop diuretics alone fail to achieve adequate decongestion:

Step 1: Escalate Loop Diuretic

• Double the IV dose every 2–3 days until urine output reaches ≥0.5 mL/kg/hour 6, 1

Step 2: Add Thiazide-Type Diuretic

• Metolazone 2.5–5 mg PO once or twice daily 3, 4, 6, 1
• OR chlorothiazide 500–1,000 mg IV once or twice daily 3, 4, 6, 1
• OR hydrochlorothiazide 25 mg PO 3, 4, 6

A 2025 network meta-analysis found that furosemide plus thiazide was associated with greater weight loss (OR 1.63) but also increased worsening renal function (OR 1.78) and hypokalemia (OR 1.69) 10.

Step 3: Add Aldosterone Antagonist

• Spironolactone or eplerenone 25–50 mg PO daily 3, 4, 6, 1
• Provides synergistic natriuresis while mitigating hypokalemia 3, 6, 1

Low-dose combination therapy is more effective and produces fewer adverse effects than high-dose loop monotherapy 3, 4, 6, 1. However, the 2024 HFpEF guideline review notes that the role of aldosterone antagonists in chronic HFpEF remains an area of disagreement among guidelines 5.

Electrolyte Management

• Hypokalemia is the most common adverse effect; aggressive replacement is required 3, 6, 1
• Hypomagnesemia frequently accompanies hypokalemia and must be corrected to enable potassium repletion 6, 1
• Hyponatremia may worsen with high-dose diuretics 3, 6, 1
• Adding spironolactone reduces the need for potassium supplementation 6

Critical Drug Interactions

• NSAIDs must be avoided—they blunt diuretic response and worsen renal function 3, 6, 1
• Continue ACE inhibitors/ARBs and beta-blockers unless hemodynamic instability develops 3, 6
• Avoid potassium-sparing diuretics during initial ACE inhibitor titration to prevent hyperkalemia 6

Therapeutic Goals

• Achieve complete resolution of clinical congestion (normal JVP, no peripheral edema, no pulmonary crackles) before discharge 6, 1
• Maintain stable electrolytes and renal function per monitoring schedule 6, 1
• Recognize that furosemide does not improve renal recovery in AKI; its role is purely symptomatic management of volume overload 1

Common Pitfalls

• Do not assume hypovolemia in HFpEF patients with AKI and hyponatremia—they are typically volume-overloaded despite low sodium 6
• Do not stop diuretics for mild creatinine rise if congestion persists; this reflects disease severity, not drug toxicity 6, 1
• Do not use continuous infusion routinely in HFpEF—the ROPA-DOP trial showed increased renal harm 7
• Do not use furosemide prophylactically in AKI without congestion—randomized trials show it may increase mortality 1